GNTA

Genenta Science S.p.A.

3.71 USD
+0.41 (+12.42%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Genenta Science S.p.A. stock is down -4.87% since 30 days ago. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 100% of the previous 2 May’s closed higher than April. 100% of analysts rate it a buy.

About Genenta Science S.p.A.

Genenta Science S.p.A. engages in the development of hematopoietic stem cell gene therapies. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.